Skip to main content
Clinical Trials/NCT03158129
NCT03158129
Completed
Phase 2

Phase II Study of Induction Checkpoint Blockade for Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection

M.D. Anderson Cancer Center1 site in 1 country101 target enrollmentJune 16, 2017

Overview

Phase
Phase 2
Intervention
Ipilimumab
Conditions
Stage I Lung Non-Small Cell Cancer AJCC v7
Sponsor
M.D. Anderson Cancer Center
Enrollment
101
Locations
1
Primary Endpoint
Major Pathologic Response (mPR)
Status
Completed
Last Updated
26 days ago

Overview

Brief Summary

This phase II trial studies how well nivolumab works when given alone and in combination with ipilimumab or chemotherapy in treating patients with previously untreated stage I-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cisplatin, docetaxel, and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab with ipilimumab or chemotherapy may work better in treating patients with non-small cell lung cancer compared to chemotherapy alone.

Detailed Description

PRIMARY OBJECTIVE: I. To determine the major pathologic response rate (MPRR) in patients treated with induction nivolumab, nivolumab plus ipilimumab, and nivolumab plus platinum-based chemotherapy. SECONDARY OBJECTIVES: I. Toxicity (assessed by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] version 4). II. Peri-operative morbidity and mortality. III. CD8 positive (+) tumor infiltrating lymphocytes (TILs) in resected tumor tissues of patients treated with nivolumab alone and nivolumab plus ipilimumab and nivolumab plus platinum-based chemotherapy. IV. Quantification of CD8+ TILs will be assessed by counting the cells positive for staining with an anti-CD8 antibody by immunohistochemistry in five random square areas (1 mm\^2 each) in both intratumoral and peritumoral compartments using the automated Aperio system. V. Response rates to induction treatment (by Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1). VI. Recurrence-free survival. VII. Overall survival. VIII. To correlate major pathologic response with recurrence-free and overall survival. IX. Complete resection (R0) rate. X. Pathologic complete response (pCR) in resected tumor specimens. XI. To correlate response assessed by imaging studies with outcomes (both major pathologic response to treatment and long-term recurrence-free survival). XII. To correlate blood, tissue, and stool-based biomarkers with efficacy and toxicity. EXPLORATORY OBJECTIVES: I. To identify novel prognostic and predictive markers present at diagnosis. II. To determine modulation of markers by induction immunotherapy and/or immunotherapy plus platinum-based chemotherapy in order to inform future translational studies. OUTLINE: Patients are randomized to Arms A and B and enrolled in Arm C or D after completion of enrollment to Arms A and B. ARM A: Patients receive nivolumab intravenously (IV) over 60 minutes on days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive nivolumab as in Arm A and receive ipilimumab IV over 90 minutes on day 1 in the absence of disease progression or unacceptable toxicity. ARM C: Patients receive nivolumab IV over 30 minutes and cisplatin IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. ARM D: Patients receive ipilimumab IV over 90 minutes on day 1, nivolumab IV over 30 minutes on days 1, 22, and 43, and cisplatin (or carboplatin) IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. After completion of study treatment and surgery, patients are followed up at 8 weeks.

Registry
clinicaltrials.gov
Start Date
June 16, 2017
End Date
November 13, 2024
Last Updated
26 days ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Histologically or cytologically confirmed previously untreated non-small cell lung cancer. If a diagnostic biopsy is available, a pre-treatment biopsy is not required. Patients with a suspected lung cancer are eligible, but pathology must be confirmed prior to initiating treatment on study. Neuroendocrine carcinomas are not eligible. Carcinomas with neuroendocrine differentiation are eligible
  • Patients with stage IA or stage IB \< 4 cm (according to American Joint Committee on Cancer \[AJCC\] 7th edition) are eligible for randomization into arms A and B only. Patients with stage IB \>= 4 cm, IIA, IIB, or IIIA disease (according to AJCC 7th edition) are eligible for randomization into arms A, and B, and for enrollment into arms C and D
  • Patients with stage IIIA must not have more than one mediastinal lymph node station involved by tumor
  • All patients must have lymph node evaluation of contralateral stations 2 and/or 4 to exclude N3 disease
  • The patient must be a suitable candidate for surgery, in the opinion of the treating physician
  • Signed and dated written informed consent must be provided by the patient prior to admission to the study in accordance with International Conference on Harmonization-Good Clinical Practice (ICH-GCP) guidelines and to the local legislation
  • Eastern Cooperative Oncology Group (ECOG) performance status score 0-1
  • Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L
  • Hemoglobin \>= 8.0 g/dL
  • Platelets \>= 100 x 10\^9/L

Exclusion Criteria

  • Prior systemic therapy or radiation therapy for treatment of the current lung cancer
  • Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drug
  • Pregnant or lactating female: Women of childbearing potential (WOCB) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \[HCG\]) within 72 hours prior to the start of nivolumab; Women of childbearing potential is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes
  • Unwillingness or inability to follow the procedures required in the protocol
  • Patients with pre-existing sensorineural hearing impairment/loss or newly diagnosed as documented by an audiology assessment performed prior to study enrollment may not be eligible for cisplatin and may be dispositioned to carboplatin, as determined by the treating physician.
  • Patients with a history of severe hypersensitivity reaction to taxotere and or polysorbate 80 must be excluded
  • Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results
  • Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
  • Subjects with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses \> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Physiologic replacement doses of systemic corticosteroids are permitted, even if \> 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted
  • Prior treatment with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody

Arms & Interventions

Arm B (nivolumab, ipilimumab)

Participants receive nivolumab as in Arm A and receive ipilimumab IV over 90 minutes on day 1 in the absence of disease progression or unacceptable toxicity.

Intervention: Ipilimumab

Arm B (nivolumab, ipilimumab)

Participants receive nivolumab as in Arm A and receive ipilimumab IV over 90 minutes on day 1 in the absence of disease progression or unacceptable toxicity.

Intervention: Nivolumab

Arm C (nivolumab, cisplatin, docetaxel, pemetrexed)

Patients receive nivolumab IV over 30 minutes and cisplatin IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.

Intervention: Cisplatin

Arm C (nivolumab, cisplatin, docetaxel, pemetrexed)

Patients receive nivolumab IV over 30 minutes and cisplatin IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.

Intervention: Docetaxel

Arm D (ipilimumab, nivolumab, chemotherapy)

Patients receive ipilimumab IV over 90 minutes on day 1, nivolumab IV over 30 minutes on days 1, 22, and 43, and cisplatin (or carboplatin) IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.

Intervention: Cisplatin

Arm C (nivolumab, cisplatin, docetaxel, pemetrexed)

Patients receive nivolumab IV over 30 minutes and cisplatin IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.

Intervention: Pemetrexed

Arm D (ipilimumab, nivolumab, chemotherapy)

Patients receive ipilimumab IV over 90 minutes on day 1, nivolumab IV over 30 minutes on days 1, 22, and 43, and cisplatin (or carboplatin) IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.

Intervention: Carboplatin

Arm D (ipilimumab, nivolumab, chemotherapy)

Patients receive ipilimumab IV over 90 minutes on day 1, nivolumab IV over 30 minutes on days 1, 22, and 43, and cisplatin (or carboplatin) IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.

Intervention: Docetaxel

Arm D (ipilimumab, nivolumab, chemotherapy)

Patients receive ipilimumab IV over 90 minutes on day 1, nivolumab IV over 30 minutes on days 1, 22, and 43, and cisplatin (or carboplatin) IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.

Intervention: Pemetrexed

Arm A (nivolumab)

Participants receive nivolumab IV over 60 minutes on days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity.

Intervention: Nivolumab

Arm C (nivolumab, cisplatin, docetaxel, pemetrexed)

Patients receive nivolumab IV over 30 minutes and cisplatin IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.

Intervention: Nivolumab

Arm D (ipilimumab, nivolumab, chemotherapy)

Patients receive ipilimumab IV over 90 minutes on day 1, nivolumab IV over 30 minutes on days 1, 22, and 43, and cisplatin (or carboplatin) IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.

Intervention: Ipilimumab

Arm D (ipilimumab, nivolumab, chemotherapy)

Patients receive ipilimumab IV over 90 minutes on day 1, nivolumab IV over 30 minutes on days 1, 22, and 43, and cisplatin (or carboplatin) IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.

Intervention: Nivolumab

Outcomes

Primary Outcomes

Major Pathologic Response (mPR)

Time Frame: The lung resection specimen was collected at surgery.

The percentage of viable tumor cells was averaged across all reviewed tumor slides from the lung resection specimen. The specimen was reviewed by two pathologists and average score was used. Tumors with ≤ 10% of viable tumor cells were considered to have undergone MPR. Patients who did not have surgery was considered to be no MPR.

Secondary Outcomes

  • Pathologic Complete Response (pCR)(The lung resection specimen was collected at surgery.)
  • Radiographic Response(Reassessment after induction therapy)
  • Overall Survival (OS)(In Arms A and B, the cutoff date was 2020-2-25. The median follow-up time frame was 22.2 months. In Arms C and D, the cutoff date was 2022-7-18. The median follow-up time frames were 39.2 and 24.0 months respectively)
  • Event-free Survival (EFS)(In Arms A and B, the cutoff date was 2020-2-25. The median follow-up time frame was 22.2 months. In Arms C and D, the cutoff date was 2022-7-18. The median follow-up time frames were 39.2 and 24.0 months respectively.)
  • Residual Tumor Classification(At surgery)
  • 30-day Postoperative Complication(Within 30 days after surgery)
  • 90-day Mortality(Within 90 days after surgery)

Study Sites (1)

Loading locations...

Similar Trials

Active, not recruiting
Phase 2
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
NCT03776487M.D. Anderson Cancer Center32
Completed
Phase 1
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland CancersMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the LungSalivary Gland CarcinomaStage IV Major Salivary Gland Cancer AJCC v8Stage IVA Major Salivary Gland Cancer AJCC v8Stage IVB Major Salivary Gland Cancer AJCC v8Stage IVC Major Salivary Gland Cancer AJCC v8
NCT03749460University of Washington20
Completed
Phase 2
Neoadjuvant and Adjuvant Checkpoint BlockadeCutaneous MelanomaMucosal MelanomaOcular MelanomaStage III Acral Lentiginous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIB Uveal Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IIIC Uveal Melanoma AJCC v7Stage IV Acral Lentiginous Melanoma AJCC v6 and v7Stage IV Cutaneous Melanoma AJCC v6 and v7Stage IV Uveal Melanoma AJCC v7
NCT02519322M.D. Anderson Cancer Center53
Active, not recruiting
Phase 2
Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before SurgeryDedifferentiated LiposarcomaRecurrent Dedifferentiated LiposarcomaRecurrent Undifferentiated Pleomorphic SarcomaResectable Dedifferentiated LiposarcomaResectable Undifferentiated Pleomorphic SarcomaUndifferentiated Pleomorphic Sarcoma
NCT03307616M.D. Anderson Cancer Center32
Active, not recruiting
Phase 2
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational BurdenAstrocytoma, IDH-Mutant, Grade 4Diffuse GliomaGlioblastoma, IDH-WildtypeSecondary Glioblastoma
NCT04145115National Cancer Institute (NCI)37

Related News

Perioperative Nivolumab and Neoadjuvant Immunotherapy Show Promise in Resectable NSCLC- Perioperative nivolumab significantly extends event-free survival (EFS) in resectable non-small cell lung cancer (NSCLC), with a median EFS increase from 17.0 to 40.1 months. - Neoadjuvant nivolumab, alone or with ipilimumab, demonstrates durable long-term survival benefits, particularly in patients achieving major pathological response (MPR) or pathological complete response (PCR). - Circulating tumor DNA (ctDNA) clearance during neoadjuvant therapy is a potential biomarker, with higher clearance rates observed in patients receiving nivolumab and correlating with improved outcomes. - Biomarker analysis suggests PD-L1 positivity may predict better EFS with nivolumab monotherapy, while KRAS co-mutations may benefit more from nivolumab plus ipilimumab combination therapy.Perioperative Nivolumab and Neoadjuvant Immunotherapy Show Promise in Resectable NSCLC- Perioperative nivolumab significantly extends event-free survival (EFS) in resectable NSCLC, with a median EFS increase from 17.0 to 40.1 months. - Neoadjuvant nivolumab, alone or with ipilimumab, demonstrates durable long-term survival benefits, particularly in patients achieving major pathological response (MPR) or pathological complete response (PCR). - Circulating tumor DNA (ctDNA) clearance during neoadjuvant therapy is a potential biomarker, with higher clearance rates observed in the nivolumab group and correlation with PCR achievement. - Biomarker analysis suggests PD-L1 positivity may predict better EFS with nivolumab monotherapy, while KRAS co-mutations may benefit more from nivolumab plus ipilimumab.